{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T22:58:51Z","timestamp":1794092331299,"version":"4.8.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T00:00:00Z","timestamp":1610582400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.parkreldis.2020.12.024","type":"journal-article","created":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T21:43:12Z","timestamp":1610574192000},"page":"79-85","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":87,"special_numbering":"C","title":["Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO study"],"prefix":"10.1016","volume":"83","author":[{"given":"Regina","family":"Katzenschlager","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Poewe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Rascol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Trenkwalder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnther","family":"Deuschl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K Ray","family":"Chaudhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tove","family":"Henriksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teus","family":"van Laar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Lockhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Staines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Lees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.parkreldis.2020.12.024_bib1","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.parkreldis.2015.06.012","article-title":"An expert consensus group for the use of apomorphine in Parkinson's, expert consensus group report on the use of apomorphine in the treatment of Parkinson's disease - clinical practice recommendations","volume":"21","author":"Trenkwalder","year":"2015","journal-title":"Park. Relat. Disord."},{"issue":"3","key":"10.1016\/j.parkreldis.2020.12.024_bib2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/WNF.0000000000000082","article-title":"Effective delivery of apomorphine in the management of Parkinson disease: practical considerations for clinicians and Parkinson nurses","volume":"38","author":"Bhidayasiri","year":"2015","journal-title":"Clin. Neuropharmacol."},{"issue":"Suppl 1","key":"10.1016\/j.parkreldis.2020.12.024_bib3","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/j.parkreldis.2016.12.003","article-title":"Apomorphine - pharmacological properties and clinical trials in Parkinson's disease","volume":"33","author":"Jenner","year":"2016","journal-title":"Park. Relat. Disord."},{"issue":"7","key":"10.1016\/j.parkreldis.2020.12.024_bib4","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1586\/14737175.2015.1051468","article-title":"Apomorphine hydrochloride for the treatment of Parkinson's disease","volume":"15","author":"Unti","year":"2015","journal-title":"Expert Rev. Neurother."},{"issue":"6","key":"10.1016\/j.parkreldis.2020.12.024_bib5","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1002\/mds.10281","article-title":"Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients","volume":"17","author":"Manson","year":"2002","journal-title":"Mov. Disord."},{"issue":"9","key":"10.1016\/j.parkreldis.2020.12.024_bib6","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S1474-4422(18)30239-4","article-title":"Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial","volume":"17","author":"Katzenschlager","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.parkreldis.2020.12.024_bib7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.parkreldis.2015.11.013","article-title":"Motor and non-motor outcomes of continuous apomorphine infusion in 125 Parkinson's disease patients","volume":"23","author":"Borgemeester","year":"2016","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2020.12.024_bib8","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.parkreldis.2017.09.025","article-title":"Continuous subcutaneous apomorphine infusion in Parkinson's disease patients with cognitive dysfunction: a retrospective long-term follow-up study","volume":"45","author":"Borgemeester","year":"2017","journal-title":"Park. Relat. Disord."},{"issue":"8","key":"10.1016\/j.parkreldis.2020.12.024_bib9","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1002\/mds.22063","article-title":"Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study","volume":"23","author":"Garcia Ruiz","year":"2008","journal-title":"Mov. Disord."},{"issue":"5","key":"10.1016\/j.parkreldis.2020.12.024_bib10","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1136\/jnnp.65.5.709","article-title":"Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up","volume":"65","author":"Pietz","year":"1998","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"5","key":"10.1016\/j.parkreldis.2020.12.024_bib11","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1007\/s00415-017-8477-0","article-title":"Continuous subcutaneous apomorphine infusion in advanced Parkinson's disease: 10-year experience with 230 patients","volume":"264","author":"Sesar","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.parkreldis.2020.12.024_bib12","first-page":"545","article-title":"Effects of long-term, continuous subcutaneous apomorphine infusions on motor complications in advanced Parkinson's disease","volume":"80","author":"Wenning","year":"1999","journal-title":"Adv. Neurol."},{"issue":"11","key":"10.1016\/j.parkreldis.2020.12.024_bib13","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1007\/s00415-004-0547-4","article-title":"A 10 year retrospective audit of long-term apomorphine use in Parkinson's disease","volume":"251","author":"Tyne","year":"2004","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.parkreldis.2020.12.024_bib14","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/mds.24023","article-title":"Questionnaire for impulsive-compulsive disorders in Parkinson's disease-rating scale","volume":"27","author":"Weintraub","year":"2012","journal-title":"Mov. Disord."},{"issue":"6","key":"10.1016\/j.parkreldis.2020.12.024_bib15","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/sleep\/14.6.540","article-title":"A new method for measuring daytime sleepiness: the Epworth sleepiness scale","volume":"14","author":"Johns","year":"1991","journal-title":"Sleep"},{"issue":"12","key":"10.1016\/j.parkreldis.2020.12.024_bib16","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults","volume":"168","author":"Posner","year":"2011","journal-title":"Am. J. Psychiatr."},{"issue":"Suppl 1","key":"10.1016\/j.parkreldis.2020.12.024_bib17","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1007\/PL00007730","article-title":"PDQ-39: a review of the development, validation and application of a Parkinson's disease quality of life questionnaire and its associated measures","volume":"245","author":"Peto","year":"1998","journal-title":"J. Neurol."},{"issue":"15","key":"10.1016\/j.parkreldis.2020.12.024_bib18","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1002\/mds.23429","article-title":"Systematic review of levodopa dose equivalency reporting in Parkinson's disease","volume":"25","author":"Tomlinson","year":"2010","journal-title":"Mov. Disord."},{"issue":"3","key":"10.1016\/j.parkreldis.2020.12.024_bib19","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1046\/j.1365-2133.1998.02128.x","article-title":"Panniculitis in association with apomorphine infusion","volume":"38","author":"Acland","year":"1998","journal-title":"Br. J. Dermatol."},{"issue":"3","key":"10.1016\/j.parkreldis.2020.12.024_bib20","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/mds.27626","article-title":"EUROPAR and the international Parkinson and movement disorders society non-motor Parkinson's disease study group, EuroInf 2: subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson's disease","volume":"34","author":"Dafsari","year":"2019","journal-title":"Mov. Disord."},{"issue":"3","key":"10.1016\/j.parkreldis.2020.12.024_bib21","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/mdc3.12416","article-title":"A retrospective evaluation of the frequency of impulsive compulsive behaviors in Parkinson's disease patients treated with continuous waking day apomorphine pumps","volume":"4","author":"Barbosa","year":"2017","journal-title":"Mov. Disord. Clin. Pract."},{"key":"10.1016\/j.parkreldis.2020.12.024_bib22","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/bs.irn.2017.04.006","article-title":"Impulse control and related disorders in Parkinson's disease","volume":"133","author":"Weintraub","year":"2017","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.parkreldis.2020.12.024_bib23","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.parkreldis.2019.06.019","article-title":"Impulse control symptoms in patients with Parkinson's disease: the influence of dopaminergic agonist","volume":"68","author":"Vargas","year":"2019","journal-title":"Park. Relat. Disord."},{"issue":"6","key":"10.1016\/j.parkreldis.2020.12.024_bib24","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00415-016-8106-3","article-title":"Quality of life in Parkinson's disease improved by apomorphine pump: the OPTIPUMP cohort study","volume":"263","author":"Drapier","year":"2016","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.parkreldis.2020.12.024_bib25","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3233\/JPD-2011-11037","article-title":"Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson's disease compared to conventional therapy: a real life study of non motor effect","volume":"1","author":"Martinez-Martin","year":"2011","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.parkreldis.2020.12.024_bib26","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jns.2018.10.010","article-title":"Effects of continuous subcutaneous apomorphine infusion in Parkinson's disease without cognitive impairment on motor, cognitive, psychiatric symptoms and quality of life","volume":"395","author":"Houvenaghel","year":"2018","journal-title":"J. Neurol. Sci."},{"issue":"9","key":"10.1016\/j.parkreldis.2020.12.024_bib27","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S1474-4422(18)30284-9","article-title":"At last, a randomised controlled trial of apomorphine infusion","volume":"17","author":"LeWitt","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.parkreldis.2020.12.024_bib28","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.parkreldis.2019.11.008","article-title":"Complex dyskinesias in Parkinson patients on levodopa\/carbidopa intestinal gel","volume":"69","author":"Marano","year":"2019","journal-title":"Park. Relat. Disord."}],"container-title":["Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135380202100016X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135380202100016X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:20:58Z","timestamp":1761178858000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S135380202100016X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":28,"alternative-id":["S135380202100016X"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2020.12.024","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO study","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2020.12.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}